Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Zymeworks’ HER2 Bispecific Under Review in China for Rare HER2 Cancers

publication date: Jun 10, 2024

Vancouver’s Zymeworks announced that its BLA for zanidatamab, a HER2-targeted bispecific antibody, was accepted for review by China’s CDE as a second-line treatment for HER2-positive biliary tract cancer (BTC). Zanidatamab can simultaneously bind two non-overlapping epitopes of the HER2 receptor, known as biparatopic binding. In 2018, BeiGene acquired Asia Pacific rights to zanidatamab and several other Zymeworks candidates in a $1.1 billion agreement. Following a Phase IIb trial, Zymeworks and BeiGene filed the BLA, which triggered an $8 million milestone from to Zymeworks. More details....

Stock Symbol: (NSDQ: ZYME)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital